Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on developing lives of patients with inflammatory diseases, including both kidney and respiratory diseases. It develops and commercializes patient preferred pharmaceutical products for global markets using its receptor technology to identify and develop drugs in areas with an unmet need. The Company is focused on developing its Phase III product candidate DMX-200 (QYTOVRA), for Focal Segmental Glomerulosclerosis (FSGS) kidney disease and is also developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). Its Receptor Heteromer Investigation Technology (Receptor-HIT) is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Its products target multiple global territories, with the initial focus predominantly on the United States and European markets.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-06-16	0.2000 $	+21.21%	18,273,008
26-06-12	0.1650 $	-2.94%	1,361,693
26-06-11	0.1700 $	+3.03%	1,507,406
26-06-10	0.1650 $	-2.94%	820,664

Delayed Quote Australian S.E.

More quotes

Income Statement and Estimates

More financial data

Market Closed - Australian S.E. Other stock markets 02:16:39 2026-06-16 EDT			5-day change	1st Jan Change
0.2000 ^AUD	+21.21%		+14.29%	-63.64%

08:06am	Dimerix Limited Licenses Exclusive Rights to Everest Medicines to Commercialise Dmx-200 in Greater China, South Korea and Southeast Asia	CI
01:35am	Everest Medicines Secures Rights to Dimerix's Kidney Disease Drug in Asia	MT

Market Cap	120M 85.05M 73.31M 67.47M 63.29M 119M 8.04B 798M 312M 3.94B 319M 312M 13.62B	P/E Ratio 2024	-13.5x	P/E Ratio 2025	-24.3x
Enterprise Value	51.89M 36.76M 31.68M 29.16M 27.35M 51.38M 3.47B 345M 135M 1.7B 138M 135M 5.89B	EV / Sales 2024	443x	EV / Sales 2025	49.4x
Free-Float	77.77%	Yield 2024 *	-	Yield 2025	-

08:06am	Dimerix Limited Licenses Exclusive Rights to Everest Medicines to Commercialise Dmx-200 in Greater China, South Korea and Southeast Asia	CI
01:35am	Everest Medicines Secures Rights to Dimerix's Kidney Disease Drug in Asia	MT
10:27pm	Dimerix Signs Exclusive License Agreement for DMX-200 in Greater China, South Korea, Southeast Asia, Shares Surge 18%	MT
04-30	Dimerix's Potential Non-Dilutive Funding May Lead to Ongoing Phase Three Trial Being Fully Funded, Euroz Hartleys Says	MT
04-28	Dimerix Limited Announces Completion of Blinded Assessment of ACTION3 Statistical Assumptions	CI
04-27	Dimerix Says Phase 3 Clinical Trial Data Review Shows Over 90% Statistical Power to Detect Proteinuria Treatment Effect; Shares Reach Two-Year Low	MT
04-27	Resonance Health Limited Announces Board Appointments, Effective April 28, 2026	CI
04-14	Dimerix Poised to Benefit From US FDA's Approval of Travere Therapeutics' Kidney Disorder Drug, Euroz Hartleys Says	MT
04-08	Dimerix Sees No Impact From US Pharma Tariffs, Says Euroz Hartleys	MT
03-17	Dimerix's Alignment With US FDA on Phase Three 3 Disease Trial Endpoints, Review Process Suggests Productive Ongoing Dialogue, Euroz Hartleys Says	MT
03-15	Dimerix to Conduct Blinded Review of Phase Three Kidney Disease Trial Data	MT
03-15	Dimerix to conduct review of Action3 statistical assumptions	RE
03-09	Dimerix Completes Patient Dosing in Phase 3 Kidney Disease Trial; Shares Up 3%	MT

04-30	Dimerix's Potential Non-Dilutive Funding May Lead to Ongoing Phase Three Trial Being Fully Funded, Euroz Hartleys Says	MT
04-14	Dimerix Poised to Benefit From US FDA's Approval of Travere Therapeutics' Kidney Disorder Drug, Euroz Hartleys Says	MT
04-08	Dimerix Sees No Impact From US Pharma Tariffs, Says Euroz Hartleys	MT
02-01	Dimerix's Cash Outflow to Materially Reduce in Current Quarter, Euroz Hartleys Says	MT
11-11	Dimerix's Potential Interim Results May Potentially Enable Accelerated Approval in the US in 2026, Euroz Hartleys Says	MT

Dimerix Limited Stock

Stocks

DXB

AU000000DXB7

Biotechnology & Medical Research

Valuation: Dimerix Limited

Chart: Dimerix Limited

Latest news : Dimerix Limited

Analysts' recommendations: Dimerix Limited

Press Releases: Dimerix Limited

Quotes and Performance

Course Extremes

Managers and Directors: Dimerix Limited

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

25-04-30	Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States	AQ
23-10-05	ADVANZ PHARMA and Dimerix enter into an Exclusive License Agreement to commercialise DMX-200 in Europe, Canada, Australia, and New Zealand	AQ
22-07-26	Dimerix : Quarterly Appendix 4C and Activities Report	PU
22-06-05	Dimerix : to Present at BIO International Convention	PU
22-04-26	Dimerix : Quarterly Appendix 4C and Activities Report	PU

1 day	+21.21%
1 week	+14.29%
Current month	+8.11%
1 month	-9.09%
3 months	-42.86%
6 months	-66.94%
Current year	-63.64%

1 week	0.16	0.25
1 month	0.16	0.25
Current year	0.16	0.56
1 year	0.16	0.66
3 years	0.06	0.78
5 years	0.05	0.78
10 years	0.05	0.78

Manager	Title	Age	Since
Nina Webster CEO	Chief Executive Officer	-	2018-08-26
Michael Tonroe DFI	Director of Finance/CFO	59	2026-01-28
Robert Shepherd COO	Chief Operating Officer	-	-

Director	Title	Age	Since
Sonia Maria Poli BRD	Director/Board Member	61	2015-07-02
Hugh Alsop CHM	Chairman	-	-
Nina Webster BRD	Director/Board Member	-	2018-08-26

Date	Insider	Type	Main position	Quantity	% Market Cap.
12-11	Sonia Maria Poli	Free	Director	100,000	0.0167%
12-11	Sonia Maria Poli	Free	Director	100,000	0.0167%
12-11	Nina Webster	Free	Chief Executive Officer	1,500,000	0.2498%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DIMERIX LIMITED	+21.21%	+14.29%	-61.90%	+244.83%	70.17M
LONZA GROUP AG	-0.12%	-0.18%	-12.80%	-12.90%	43.58B
REVOLUTION MEDICINES, INC.	-3.23%	+3.08%	+287.60%	+526.12%	34.03B
IQVIA HOLDINGS INC.	+0.52%	-4.17%	+12.08%	-17.38%	29.77B
BEONE MEDICINES AG	-0.41%	-0.27%	+1.14%	+33.58%	29.82B
CELLTRION, INC.	-0.29%	+9.47%	+13.95%	+21.93%	25.42B
ASCENDIS PHARMA A/S	+2.85%	+7.94%	-	-	13.87B
MEDPACE HOLDINGS, INC.	-0.80%	-1.13%	+53.34%	+108.06%	13.35B
EUROFINS SCIENTIFIC SE	-1.04%	-3.48%	+2.42%	+1.98%	12.85B
IONIS PHARMACEUTICALS, INC.	-1.68%	-2.20%	+106.98%	+77.82%	12.22B
Average	+1.70%	+1.25%	+44.76%	+109.34%	21.5B
Weighted average by Cap.	-0.59%	+2.01%	+59.78%	+103.51%

	2024	2025
Net sales	583K 413K 356K 328K 308K 578K 39.06M 3.88M 1.51M 19.13M 1.55M 1.52M 66.19M	5.59M 3.96M 3.41M 3.14M 2.94M 5.53M 374M 37.11M 14.5M 183M 14.85M 14.54M 634M
Net income	-17.08M -12.09M -10.42M -9.59M -9M -16.91M -1.14B -113M -44.3M -560M -45.39M -44.43M -1.94B	-13.25M -9.39M -8.09M -7.45M -6.98M -13.12M -887M -88.02M -34.38M -434M -35.22M -34.48M -1.5B
Net Debt	-21.99M -15.58M -13.43M -12.36M -11.59M -21.77M -1.47B -146M -57.06M -721M -58.46M -57.22M -2.49B	-68.19M -48.3M -41.63M -38.31M -35.94M -67.51M -4.56B -453M -177M -2.24B -181M -177M -7.73B